Belimumab | 合法藥品大搜索

Belimumab,soldunderthebrandnameBenlysta,isahumanmonoclonalantibodythatinhibitsB-cellactivatingfactor(BAFF),alsoknownasB-lymphocyte​ ...

Pharmaceutical drug

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF),[6] also known as B-lymphocyte stimulator (BLyS).[7] It is approved in the United States[8] and Canada,[9] and the European Union[5] to treat systemic lupus erythematosus and lupus nephritis.[10]

The most common side effects include bacterial infections, such as bronchitis (infection in the lungs) and infection of the urinary tract (structures that produce or carry urine), diarrhea and nausea (feeling sick).[5]

Belimumab is indicated for the treatment of active systemic lupus erythematosus and active lupus nephritis.[4][5]

Common adverse effects reported with belimumab include nausea, diarrhea, and fever, as well as hypersensitivity and infusion-site reactions, which were severe in 0.9% of patients. Regulatory agencies recommend that patients be treated with a...